Toronto, July 3, 2026, 17:01 EDT
- Apotex Health Corp. TSX:APTX finished the session 4.75% higher at C$33.95. Volume came in at 146,773 shares, well below the 65-day average of 619,968.
- Friday’s close left the 62.29 million-share IPO block worth about C$620 million more than its C$1.495 billion issue price, using Apotex’s June 16 offering figures.
- Apotex wrapped up its $100 million deal for Cumberland Pharmaceuticals Inc.’s U.S. branded drug line on July 1. The acquisition brings new hospital and specialty brands to Apotex.
Apotex Health Corp. TSX:APTX climbed 4.75% Friday to C$33.95, a new record close since its June debut. Canada’s S&P/TSX Composite Index also gained, finishing up 0.9% at 35,274.84. Trading volume was light for Apotex. Just 146,773 shares traded, well below its 65-day average, though the stock did hit a fresh intraday high at C$34.38.
Friday’s price action offers some signal, but it’s messy. The TSX ran on its normal Toronto schedule, but the NYSE was closed for July 3’s Independence Day observance. Reading the cross-border volume got tricky.
| Measure | Apotex | Comparison | Investor read |
|---|---|---|---|
| Friday price move | Up 4.75% | S&P/TSX climbed 0.9% | Outpaced the Canadian index |
| Friday volume | 146,773 shares | Avg 65-day volume: 619,968 | About 24% of usual |
| Friday high | C$34.38 | 52-week peak at C$34.38 | Set a new high, but volume was low |
| Close vs IPO price | C$33.95 | C$24.00 | Up 41.5% |
IPO pricing is getting more attention than the first-day pop. Apotex (link) sold 62,291,670 shares at C$24 apiece at its larger offering on June 16, bringing in C$1.495 billion gross. By Friday’s close, those shares were worth around C$2.115 billion. That’s a paper gain of C$619.8 million in just under three weeks.
| IPO and ownership check | Figure |
|---|---|
| IPO price | C$24.00 |
| IPO shares sold | 62,291,670 |
| Gross proceeds | C$1.495 billion |
| Value of IPO shares at C$33.95 | C$2.115 billion |
| Gain over issue value | C$619.8 million |
| SK Capital post-offering stake | 52.4% |
| Sherfam post-offering stake | 14.2% |
| SK plus Sherfam | 66.6% |
The float remains tight. SK Artemis Holdings II, run by SK Capital Partners, held 119,643,514 shares, or 52.4% of Apotex after the offering on a non-diluted basis. Sherfam had 32,414,910 shares, about 14.2%. So traders are working with a smaller free float than the C$7 billion-plus valuation might indicate.
Cumberland Pharmaceuticals Inc. NASDAQ:CPIX closed the sale of its branded pharmaceuticals unit to Apotex for $100 million in cash. Cumberland shareholders gave the go-ahead before the deal wrapped. Apotex picked up brands Kristalose, Caldolor, Sancuso, Vibativ, Acetadote, Vaprisol and Talicia.
Jeff Watson, president and CEO of Apotex, said the Cumberland deal will support “patients and healthcare providers across the United States.” Cumberland CEO A.J. Kazimi said the deal “significantly strengthens our financial position” and had support from over 99% of votes. Apotex
Apotex shares got another price move just ahead of the Cumberland close. The company announced June 30 that Health Canada cleared SEVMIA, the firm’s generic of Wegovy semaglutide for chronic weight management in adults. Apotex Canada president Martin Arès said in a statement that the green light meets “significant and growing needs for patients.” Apotex
Investors keep watching because there aren’t many options. Kevin Burkett, who runs money at Burkett Asset Management, called the Apotex IPO a shot at a “sector underrepresented on the TSX.” Shares are now up more than 40% since the deal. The company has since picked up a U.S. branded-drug portfolio and won Canadian approval for an obesity drug. Reuters
The overhang is still there. Apotex said SK Holdings could buy more securities or sell shares now and then based on market or business shifts, and subject to laws and lock-up rules. Sherfam gave a similar statement.
